Education
About Us
Working with TipRanks
Follow Us
Oculis Holding (OCS)
NASDAQ:OCS
OCS Stock Chart & Stats
$28.61
$0.20(1.10%)
At close: 4:00 PM EST
$28.61
$0.20(1.10%)
Day’s Range― - ―
52-Week Range$14.00 - $30.68
Previous CloseN/A
Volume95.89K
Average Volume (3M)58.01K
Market Cap
$1.64B
Enterprise Value$1.23B
Total Cash (Recent Filing)$46.44M
Total Debt (Recent Filing)$2.47M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding57,169,476
10 Day Avg. Volume127,612
30 Day Avg. Volume58,014
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)8.50
Price to Sales (P/S)908.96
P/FCF Ratio-13.06
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue2.43K
Enterprise Value/Gross Profit-85.08
Enterprise Value/Ebitda-11.90
Forecast
1Y Price Target
$43.75Price Target Upside52.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.71
Revenue Forecast (FY)$5.56M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2 ACUITY showed clinically meaningful and statistically significant improvement in low-contrast visual acuity with a sustained treatment effect versus standard steroid treatment, supporting the likelihood of confirmatory results in registrational trials.
Phase 3 Program And Commercial PotentialCompletion of large enrollment in Phase 3 DIAMOND trials for OCS-01 creates the potential for a regulatory submission and introduces a patient-friendly topical option for diabetic macular edema that could complement injectable therapies.
Regulatory ProgressFDA Breakthrough Therapy designation for privosegtor enables closer regulator engagement and eligibility for accelerated review pathways, potentially speeding approval if pivotal data confirm benefit.
Bears Say
Cash RunwayHigh cash burn and a limited cash runway raise the prospect of near-term funding needs that could constrain operations and strategic flexibility.
Execution RiskManaging multiple near-term registrational programs creates execution risk from potential delays or operational setbacks that could negatively affect valuation and investor sentiment.
Financing RiskDependence on successful trial readouts to support financing increases the risk of urgent capital raises on unfavorable terms if study outcomes or timing disappoint investors.
Oculis Holding News
OCS FAQ
What was Oculis Holding’s price range in the past 12 months?
Oculis Holding lowest stock price was $14.00 and its highest was $30.68 in the past 12 months.
What is Oculis Holding’s market cap?
Oculis Holding’s market cap is $1.64B.
When is Oculis Holding’s upcoming earnings report date?
Oculis Holding’s upcoming earnings report date is May 07, 2026 which is in 65 days.
How were Oculis Holding’s earnings last quarter?
Oculis Holding released its earnings results on Mar 03, 2026. The company reported -$0.539 earnings per share for the quarter, missing the consensus estimate of -$0.486 by -$0.053.
Is Oculis Holding overvalued?
According to Wall Street analysts Oculis Holding’s price is currently Undervalued.
Does Oculis Holding pay dividends?
Oculis Holding does not currently pay dividends.
What is Oculis Holding’s EPS estimate?
Oculis Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oculis Holding have?
Oculis Holding has 57,169,476 shares outstanding.
What happened to Oculis Holding’s price movement after its last earnings report?
Oculis Holding reported an EPS of -$0.539 in its last earnings report, missing expectations of -$0.486. Following the earnings report the stock price went down -0.103%.
Which hedge fund is a major shareholder of Oculis Holding?
Currently, no hedge funds are holding shares in OCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oculis Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.75 (52.92% Upside)
$43.75 (52.92% Upside)
Hedge Fund Trend
Increased
By 611.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.49%
12-Months-Change
Fundamentals
Return on Equity
-80.98%
Trailing 12-Months
Asset Growth
47.79%
Trailing 12-Months
Company Description
Oculis Holding
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
OCS Stock 12 Month Forecast
Average Price Target
$43.75
▲(52.92% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Spyre Therapeutics
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Upstream Bio, Inc.
―
Ownership Overview
―
Insiders
0.62% Mutual Funds
22.98% Other Institutional Investors
76.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---